Radioisotope therapy of bone metastases
Nuclear Medicine Review · 2011-12 · 14 (2) · 96-104
DOI: 10.5603/nmr.2011.00023 ↗At a glance
Übersichtsarbeit in Nuclear Medicine Review, 2011-12. Written by Maciej Bączyk. Institution: Department of Nuclear Medicine, Heliodor Święcicki Hospital, Medical University, Poznań, Poland. endopoz@onet.pl. Cited 10 times so far (Crossref).
Abstract (original language)
Radionuclide therapy has been an integral part of systemic treatment of patients with advanced and disseminated cancer for 50 years. Specific radioisotopes (b- or a-emitters) with selective concentration at sites of bone cancer damage are used in the treatment. Radioisotopes are an important addition to the armamentarium of clinicians who take care of patients with advanced cancer and painful cancer bone metastases (especially osteoblastic and mixed type). They offer a high degree of efficacy with minimal toxicity and simple administration, fulfilling the fundamental criteria for palliative treatment that should combine minimal patient discomfort and toxicity with maximal clinical effect.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Nuclear Medicine, Heliodor Święcicki Hospital, Medical University, Poznań, Poland. endopoz@onet.pl
Cite
APA
Bączyk, M. (2011). Radioisotope therapy of bone metastases. Nuclear Medicine Review, 14(2), 96-104. https://doi.org/10.5603/nmr.2011.00023
Vancouver
Bączyk M. Radioisotope therapy of bone metastases. Nuclear Medicine Review. 2011;14(2):96-104. doi:10.5603/nmr.2011.00023
BibTeX
@article{Bczyk2011,
author = {Bączyk, Maciej},
title = {Radioisotope therapy of bone metastases},
journal = {Nuclear Medicine Review},
year = {2011},
volume = {14},
number = {2},
pages = {96--104},
doi = {10.5603/nmr.2011.00023}
}
EUVIMED